Immature oocytes at GV or MI stages were donated by healthy non-diabetic women aged 25–39 years after signed informed consent. The women were undergoing controlled ovarian stimulation (COH) treatments aimed at oocyte cryopreservation or intracytoplasmic sperm injection (ICSI) at the Department of Reproductive Medicine of Karolinska University Hospital. The standard COS treatments and clinical routines have been previously described (Feichtinger et al, 2017 (link)). Briefly, either a long-protocol, using a nasal GnRH agonist (Nafarelin 800 μg daily; Synarela, Pfizer) or buserelin 1200 μg daily; Suprecur, Sanofi), or a short protocol using GnRH antagonist (0.25 mg once daily, SC ganirelix, Fyremadel, Ferring) initiated routinely on the fifth day of COS were conducted. The dose of COS (75–400 IU daily of recombinant follicle stimulating hormone (Gonal-F Merck or hMG Menopur, Ferring) was individualized to patient’s age, menstrual cycle length, antral follicle count and anti-Mullerian hormone levels. Ovarian follicle growth tracking was performed by scheduled transvaginal ultrasound examinations that lead to the planning timepoint for oocyte maturation triggered by administration of recombinant hCG (250 μg SC Ovitrelle; Merck). Oocyte retrieval was carried out by transvaginal ultrasographically-guided follicular puncture 37 h later.
Fyremadel
Manufactured by Ferring
Sourced in United Kingdom
Fyremadel is a laboratory equipment product designed for specific scientific applications. It serves a core function within the research and testing activities conducted in various laboratories. The details and intended use of Fyremadel are not available in this factual and unbiased response.
Automatically generated - may contain errors
2 protocols using fyremadel
1
Oocyte Donation and Retrieval Protocol
2
Ovarian Stimulation Protocol with GnRH Antagonist
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
In all cases an antagonist protocol was used to carry out ovarian stimulation. Individualized doses of gonadotrophins were determined by an experienced specialist physician. Transvaginal ultrasound for cycle monitoring was performed every 2 days starting on stimulation day 5. Fixed daily doses of 0.25 mg of gonadotrophinreleasing hormone (GnRH) antagonist (Orgalutran, Cetrotide, Merck Serono Europe Ltd, London, UK; or Fyremadel, Ferring, Malmö, Sweden) were started when the leading follicle reached a mean diameter of 13-14 mm. All patients received GnRH agonist 0.2 mg (Decapeptyl, Ipsen PharmaParis, France) to achieve final oocyte maturation when the mean size of at least two follicles was 18 mm. Oocyte retrieval was performed 36 h later under ultrasound guidance.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!